1530:
194:. The combination includes 400 mg sofosbuvir and 60 mg daclatasvir and has been used in clinical trials since 2015. Sovodak was approved by the Iranian Food and Drug Administration in October 2015 and is currently marketed in Iran as the treatment of choice for all genotypes of hepatitis C as recommended by the national Iranian guideline for treating hepatitis C.
1513:
1501:
42:
202:
The similarities between the hepatitis C and SARS-CoV-2 virus has led some researches to investigate the effectiveness of sofosbuvir/daclatasvir against COVID-19. Three recently published studies have found this combination to be beneficial against COVID-19 although the findings require confirmation
408:
Merat S (May 2020). "SD1000: High
Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial".
444:
Poustchi H, Majd
Jabbari S, Merat S, Sharifi AH, Shayesteh AA, Shayesteh E, et al. (September 2020). "The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment".
654:"Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial"
595:"Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial"
1608:
1574:
206:
In
October 2020, a meta-analysis found a significantly lower risk of all-cause mortality with the drug combination when given to hospitalized patients with COVID-19.
778:
1598:
1567:
1455:
243:"Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life"
179:
488:
1593:
1100:
1613:
1085:
1560:
314:
296:
1491:
771:
1472:
652:
Abbaspour
Kasgari H, Moradi S, Shabani AM, Babamahmoodi F, Davoudi Badabi AR, Davoudi L, et al. (November 2020).
336:
1603:
1075:
756:
1460:
1212:
764:
102:
1324:
1309:
1095:
713:"Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis"
1271:
1266:
1080:
593:
Sadeghi A, Ali Asgari A, Norouzi A, Kheiri Z, Anushirvani A, Montazeri M, et al. (November 2020).
1070:
1540:
119:
534:
Eslami G, Mousaviasl S, Radmanesh E, Jelvay S, Bitaraf S, Simmons B, et al. (November 2020).
1261:
1166:
898:
693:
634:
575:
496:
470:
396:
365:
711:
Simmons B, Wentzel H, Mobarak S, Eslami G, Sadeghi A, Ali Asgari A, et al. (January 2021).
1039:
1422:
962:
742:
685:
626:
567:
462:
426:
274:
92:
1544:
128:
1281:
732:
724:
675:
665:
616:
606:
557:
547:
454:
418:
344:
264:
254:
395:
for "Sofosbuvir, Daclatasvir, Ribavirin for
Hepatitis C Virus (HCV) Cirrhotics (SD100)" at
1505:
1517:
1466:
1406:
1216:
985:
790:
737:
712:
680:
653:
621:
594:
562:
535:
269:
242:
79:
33:
17:
1587:
1537:
999:
697:
638:
579:
474:
536:"The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19"
1381:
1376:
1346:
1320:
1305:
1295:
1132:
1054:
952:
903:
873:
802:
798:
794:
1529:
391:
310:
292:
293:"Daklinza film-coated tablets – Summary of Product Characteristics (SPC) - (eMC)"
1427:
1401:
1396:
1356:
1351:
1315:
1300:
1290:
1235:
1221:
1203:
1141:
1122:
1114:
972:
927:
922:
868:
863:
858:
853:
833:
811:
156:
152:
57:
1437:
1432:
1366:
1253:
1198:
1193:
1188:
1184:
1176:
1146:
1049:
1044:
1034:
1029:
1009:
994:
967:
957:
947:
937:
893:
888:
883:
878:
848:
843:
838:
511:"Hepatitis Monthly | International Monthly Journal in the Field of Hepatology"
168:
164:
70:
341:
World Health
Organization model list of essential medicines: 22nd list (2021)
1391:
1361:
1231:
1226:
1171:
1157:
1014:
1004:
942:
820:
787:
746:
689:
630:
571:
466:
430:
278:
190:
This combination is produced by an
Iranian company under the trade name of
728:
670:
611:
552:
932:
422:
311:"Sovaldi 400 mg film coated tablets - Summary of Product Characteristics"
349:
259:
1386:
1024:
1019:
1512:
458:
1371:
1341:
41:
982:
913:
824:
172:
160:
75:
62:
760:
223:
1548:
510:
180:
369:
313:. UK Electronic Medicines Compendium. September 2016.
1489:
1415:
1334:
1280:
1252:
1245:
1155:
1131:
1113:
1063:
981:
912:
819:
810:
295:. Electronic Medicines Compendium. September 2016.
118:
113:
101:
91:
86:
69:
56:
51:
151:) is a two-drug combination for the treatment of
155:. It is given as a single daily pill containing
127:
1609:World Health Organization essential medicines
1568:
772:
8:
32:
241:Pol S, Corouge M, Vallet-Pichard A (2016).
1575:
1561:
1249:
816:
779:
765:
757:
447:Journal of Gastroenterology and Hepatology
40:
736:
717:The Journal of Antimicrobial Chemotherapy
679:
669:
658:The Journal of Antimicrobial Chemotherapy
620:
610:
599:The Journal of Antimicrobial Chemotherapy
561:
551:
540:The Journal of Antimicrobial Chemotherapy
348:
268:
258:
1496:
247:Hepatic Medicine: Evidence and Research
215:
171:inhibitor of the viral RNA polymerase
31:
343:. Geneva: World Health Organization.
317:from the original on 10 November 2016
7:
1526:
1524:
493:Iranian Food and Drug Administration
1101:Sofosbuvir/velpatasvir/voxilaprevir
1547:. You can help Knowledge (XXG) by
25:
1086:Ombitasvir/paritaprevir/ritonavir
228:Darvoni - Beacon Medicare Limited
1528:
1511:
1499:
299:from the original on 2016-11-09.
1:
827:protease inhibitors (–previr)
1599:NS5B (polymerase) inhibitors
411:Clinical Infectious Diseases
1594:Combination antiviral drugs
1630:
1523:
353:. WHO/MHP/HPS/EML/2021.02.
1614:Antiinfective agent stubs
1450:
337:World Health Organization
39:
1213:neuraminidase inhibitors
1076:Glecaprevir/pibrentasvir
1416:Multiple/Unknown/Other
1185:adamantane derivatives
1096:Sofosbuvir/velpatasvir
1091:Sofosbuvir/daclatasvir
389:Clinical trial number
141:Daclatasvir/sofosbuvir
34:Sofosbuvir/daclatasvir
18:Sofosbuvir/Daclatasvir
1284:inhibitors (–trelvir)
1272:Peginterferon alfa-2b
1267:Peginterferon alfa-2a
1081:Ledipasvir/sofosbuvir
1071:Elbasvir/grazoprevir
988:inhibitors (–buvir)
916:inhibitors (–asvir)
729:10.1093/jac/dkaa418
671:10.1093/jac/dkaa332
612:10.1093/jac/dkaa334
553:10.1093/jac/dkaa331
499:on 23 October 2017.
260:10.2147/HMER.S62014
203:by larger studies.
186:Society and culture
36:
1477:Never to phase III
1335:RNA pol inhibitors
1262:Interferon alfa 2b
1167:Baloxavir marboxil
423:10.1093/cid/ciz628
397:ClinicalTrials.gov
1556:
1555:
1487:
1486:
1446:
1445:
1109:
1108:
1064:Combination drugs
664:(11): 3373–3378.
605:(11): 3379–3385.
546:(11): 3366–3372.
515:Hepatitis Monthly
459:10.1111/jgh.14994
417:(10): 2206–2212.
138:
137:
16:(Redirected from
1621:
1577:
1570:
1563:
1532:
1525:
1516:
1515:
1504:
1503:
1502:
1495:
1250:
1246:Multiple/general
817:
781:
774:
767:
758:
751:
750:
740:
708:
702:
701:
683:
673:
649:
643:
642:
624:
614:
590:
584:
583:
565:
555:
531:
525:
524:
522:
521:
507:
501:
500:
495:. Archived from
485:
479:
478:
453:(9): 1590–1594.
441:
435:
434:
405:
399:
387:
381:
380:
378:
377:
368:. Archived from
361:
355:
354:
352:
333:
327:
326:
324:
322:
307:
301:
300:
289:
283:
282:
272:
262:
238:
232:
231:
220:
131:
97:Darvoni, Sovodak
44:
37:
35:
27:Combination drug
21:
1629:
1628:
1624:
1623:
1622:
1620:
1619:
1618:
1604:NS5A inhibitors
1584:
1583:
1582:
1581:
1522:
1510:
1500:
1498:
1490:
1488:
1483:
1482:
1467:Clinical trials
1442:
1411:
1330:
1276:
1241:
1151:
1127:
1105:
1059:
977:
908:
806:
785:
755:
754:
710:
709:
705:
651:
650:
646:
592:
591:
587:
533:
532:
528:
519:
517:
509:
508:
504:
487:
486:
482:
443:
442:
438:
407:
406:
402:
388:
384:
375:
373:
363:
362:
358:
335:
334:
330:
320:
318:
309:
308:
304:
291:
290:
286:
240:
239:
235:
222:
221:
217:
212:
200:
188:
163:inhibitor, and
134:
104:
47:
28:
23:
22:
15:
12:
11:
5:
1627:
1625:
1617:
1616:
1611:
1606:
1601:
1596:
1586:
1585:
1580:
1579:
1572:
1565:
1557:
1554:
1553:
1533:
1521:
1520:
1508:
1485:
1484:
1481:
1480:
1479:
1478:
1475:
1464:
1458:
1452:
1451:
1448:
1447:
1444:
1443:
1441:
1440:
1435:
1430:
1425:
1419:
1417:
1413:
1412:
1410:
1409:
1407:Valopicitabine
1404:
1399:
1394:
1389:
1384:
1379:
1374:
1369:
1364:
1359:
1354:
1349:
1344:
1338:
1336:
1332:
1331:
1329:
1328:
1318:
1313:
1303:
1298:
1293:
1287:
1285:
1278:
1277:
1275:
1274:
1269:
1264:
1258:
1256:
1247:
1243:
1242:
1240:
1239:
1229:
1224:
1208:
1207:
1201:
1196:
1180:
1179:
1174:
1169:
1163:
1161:
1153:
1152:
1150:
1149:
1137:
1135:
1129:
1128:
1126:
1125:
1119:
1117:
1111:
1110:
1107:
1106:
1104:
1103:
1098:
1093:
1088:
1083:
1078:
1073:
1067:
1065:
1061:
1060:
1058:
1057:
1052:
1047:
1042:
1037:
1032:
1027:
1022:
1017:
1012:
1007:
1002:
997:
991:
989:
986:RNA polymerase
979:
978:
976:
975:
970:
965:
960:
955:
950:
945:
940:
935:
930:
925:
919:
917:
910:
909:
907:
906:
901:
896:
891:
886:
881:
876:
871:
866:
861:
856:
851:
846:
841:
836:
830:
828:
814:
808:
807:
786:
784:
783:
776:
769:
761:
753:
752:
723:(2): 286–291.
703:
644:
585:
526:
502:
480:
436:
400:
382:
366:"Sovodak دارو"
356:
328:
302:
284:
233:
214:
213:
211:
208:
199:
196:
187:
184:
136:
135:
133:
132:
124:
122:
116:
115:
111:
110:
107:
105:administration
99:
98:
95:
89:
88:
84:
83:
80:RNA polymerase
73:
67:
66:
60:
54:
53:
52:Combination of
49:
48:
46:Sovodak 60/400
45:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
1626:
1615:
1612:
1610:
1607:
1605:
1602:
1600:
1597:
1595:
1592:
1591:
1589:
1578:
1573:
1571:
1566:
1564:
1559:
1558:
1552:
1550:
1546:
1543:article is a
1542:
1539:
1538:antiinfective
1534:
1531:
1527:
1519:
1514:
1509:
1507:
1497:
1493:
1476:
1474:
1471:
1470:
1468:
1465:
1462:
1459:
1457:
1454:
1453:
1449:
1439:
1436:
1434:
1431:
1429:
1426:
1424:
1421:
1420:
1418:
1414:
1408:
1405:
1403:
1400:
1398:
1395:
1393:
1390:
1388:
1385:
1383:
1380:
1378:
1375:
1373:
1370:
1368:
1365:
1363:
1360:
1358:
1355:
1353:
1350:
1348:
1345:
1343:
1340:
1339:
1337:
1333:
1326:
1322:
1319:
1317:
1314:
1311:
1307:
1304:
1302:
1299:
1297:
1294:
1292:
1289:
1288:
1286:
1283:
1279:
1273:
1270:
1268:
1265:
1263:
1260:
1259:
1257:
1255:
1251:
1248:
1244:
1237:
1233:
1230:
1228:
1225:
1223:
1219:
1218:
1217:release phase
1214:
1210:
1209:
1205:
1202:
1200:
1197:
1195:
1191:
1190:
1189:M2 inhibitors
1186:
1182:
1181:
1178:
1175:
1173:
1170:
1168:
1165:
1164:
1162:
1159:
1154:
1148:
1145:
1143:
1139:
1138:
1136:
1134:
1130:
1124:
1121:
1120:
1118:
1116:
1112:
1102:
1099:
1097:
1094:
1092:
1089:
1087:
1084:
1082:
1079:
1077:
1074:
1072:
1069:
1068:
1066:
1062:
1056:
1053:
1051:
1048:
1046:
1043:
1041:
1038:
1036:
1033:
1031:
1028:
1026:
1023:
1021:
1018:
1016:
1013:
1011:
1008:
1006:
1003:
1001:
1000:Bemnifosbuvir
998:
996:
993:
992:
990:
987:
984:
980:
974:
971:
969:
966:
964:
961:
959:
956:
954:
951:
949:
946:
944:
941:
939:
936:
934:
931:
929:
926:
924:
921:
920:
918:
915:
911:
905:
902:
900:
897:
895:
892:
890:
887:
885:
882:
880:
877:
875:
872:
870:
867:
865:
862:
860:
857:
855:
852:
850:
847:
845:
842:
840:
837:
835:
832:
831:
829:
826:
822:
818:
815:
813:
809:
804:
800:
796:
792:
789:
782:
777:
775:
770:
768:
763:
762:
759:
748:
744:
739:
734:
730:
726:
722:
718:
714:
707:
704:
699:
695:
691:
687:
682:
677:
672:
667:
663:
659:
655:
648:
645:
640:
636:
632:
628:
623:
618:
613:
608:
604:
600:
596:
589:
586:
581:
577:
573:
569:
564:
559:
554:
549:
545:
541:
537:
530:
527:
516:
512:
506:
503:
498:
494:
490:
484:
481:
476:
472:
468:
464:
460:
456:
452:
448:
440:
437:
432:
428:
424:
420:
416:
412:
404:
401:
398:
394:
393:
386:
383:
372:on 2019-07-03
371:
367:
360:
357:
351:
346:
342:
338:
332:
329:
316:
312:
306:
303:
298:
294:
288:
285:
280:
276:
271:
266:
261:
256:
252:
248:
244:
237:
234:
229:
225:
219:
216:
209:
207:
204:
197:
195:
193:
185:
183:
181:
178:It is on the
176:
174:
170:
166:
162:
158:
154:
150:
146:
143:(trade names
142:
130:
126:
125:
123:
121:
117:
112:
108:
106:
100:
96:
94:
90:
87:Clinical data
85:
81:
77:
74:
72:
68:
64:
61:
59:
55:
50:
43:
38:
30:
19:
1549:expanding it
1535:
1382:Molnupiravir
1377:Mericitabine
1347:Deuremidevir
1321:Simnotrelvir
1306:Nirmatrelvir
1296:Ibuzatrelvir
1282:3CL protease
1211:
1183:
1140:
1133:Picornavirus
1090:
1055:Uprifosbuvir
953:Pibrentasvir
904:Voxilaprevir
874:Paritaprevir
720:
716:
706:
661:
657:
647:
602:
598:
588:
543:
539:
529:
518:. Retrieved
514:
505:
497:the original
492:
489:"Sofosbuvir"
483:
450:
446:
439:
414:
410:
403:
390:
385:
374:. Retrieved
370:the original
359:
350:10665/345533
340:
331:
319:. Retrieved
305:
287:
250:
246:
236:
227:
218:
205:
201:
191:
189:
177:
148:
144:
140:
139:
129:2306918-02-3
29:
1463:from market
1428:Merimepodib
1402:Triazavirin
1397:Taribavirin
1357:Galidesivir
1352:Favipiravir
1316:Rupintrivir
1301:Lufotrelvir
1291:Ensitrelvir
1236:Laninamivir
1222:Oseltamivir
1204:Rimantadine
1142:viral entry
1123:Bulevirtide
1115:Hepatitis D
973:Velpatasvir
928:Daclatasvir
923:Coblopasvir
899:Vedroprevir
869:Narlaprevir
864:Grazoprevir
859:Glecaprevir
854:Faldaprevir
834:Asunaprevir
812:Hepatitis C
793:(primarily
392:NCT02596880
321:10 November
157:daclatasvir
153:hepatitis C
114:Identifiers
93:Trade names
82:) inhibitor
58:Daclatasvir
1588:Categories
1438:Presatovir
1433:Moroxydine
1367:Remdesivir
1325:+ritonavir
1310:+ritonavir
1254:Interferon
1199:Amantadine
1194:Adapromine
1177:Umifenovir
1147:Pleconaril
1050:Radalbuvir
1045:TMC-647055
1035:Sofosbuvir
1030:Setrobuvir
1010:Deleobuvir
995:Beclabuvir
968:Samatasvir
958:Ravidasvir
948:Ombitasvir
938:Ledipasvir
894:Vaniprevir
889:Telaprevir
884:Sovaprevir
879:Simeprevir
849:Danoprevir
844:Ciluprevir
839:Boceprevir
791:antivirals
520:2019-07-17
376:2019-07-17
210:References
169:nucleotide
165:sofosbuvir
159:, a viral
120:CAS Number
71:Sofosbuvir
1473:Phase III
1461:Withdrawn
1392:Ribavirin
1362:GS-441524
1232:Peramivir
1227:Zanamivir
1172:Pimodivir
1158:influenza
1040:Tegobuvir
1015:Filibuvir
1005:Dasabuvir
943:Odalasvir
788:RNA virus
698:221180153
639:221181054
580:221182215
475:210948579
364:Codrops.
253:: 21–26.
103:Routes of
65:inhibitor
1506:Medicine
963:Ruzasvir
933:Elbasvir
747:33063117
690:32812025
631:32812039
572:32812051
467:31994788
431:31504303
339:(2021).
315:Archived
297:Archived
279:27019602
198:Research
1518:Viruses
1492:Portals
1387:NITD008
1025:IDX-184
1020:GS-6620
797:, also
738:7665526
681:7454669
622:7454592
563:7529105
270:4786064
192:Sovodak
149:Sovodak
145:Darvoni
1456:WHO-EM
1372:MK-608
1342:CMX521
1160:agents
745:
735:
696:
688:
678:
637:
629:
619:
578:
570:
560:
473:
465:
429:
277:
267:
224:"Home"
1536:This
1423:EICAR
1156:Anti-
803:D06BB
799:S01AD
694:S2CID
635:S2CID
576:S2CID
471:S2CID
1545:stub
1541:drug
983:NS5B
914:NS5A
801:and
743:PMID
686:PMID
627:PMID
568:PMID
463:PMID
427:PMID
323:2016
275:PMID
173:NS5B
167:, a
161:NS5A
109:Oral
76:NS5B
63:NS5A
821:NS3
795:J05
733:PMC
725:doi
676:PMC
666:doi
617:PMC
607:doi
558:PMC
548:doi
455:doi
419:doi
345:hdl
265:PMC
255:doi
1590::
1469::
1234:,
825:4A
741:.
731:.
721:76
719:.
715:.
692:.
684:.
674:.
662:75
660:.
656:.
633:.
625:.
615:.
603:75
601:.
597:.
574:.
566:.
556:.
544:75
542:.
538:.
513:.
491:.
469:.
461:.
451:35
449:.
425:.
415:70
413:.
273:.
263:.
249:.
245:.
226:.
182:.
175:.
147:,
1576:e
1569:t
1562:v
1551:.
1494::
1327:)
1323:(
1312:)
1308:(
1238:)
1220:(
1215:/
1206:)
1192:(
1187:/
1144::
823:/
805:)
780:e
773:t
766:v
749:.
727::
700:.
668::
641:.
609::
582:.
550::
523:.
477:.
457::
433:.
421::
379:.
347::
325:.
281:.
257::
251:8
230:.
78:(
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
